Trending...
- Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression
- SlotCycle Joins Association of Gaming Equipment Manufacturers (AGEM) to Advance Sustainable Gaming Solutions
- Southbox Entertainment, FinTech Pioneer & Entrepreneur Jon Gosier Join Psychological Thriller The Dutchman as Financing Partner
BOSTON, Aug. 1, 2024 ~ Boston, USA - The 4th mRNA Therapeutics Summit, a highly anticipated event in the global mRNA industry, was held from July 29-31. Over 400 industry experts and 65 leading researchers in mRNA development gathered to discuss the latest breakthroughs and expanding applications of this cutting-edge technology. Among the distinguished attendees was Dr. Xiangrong Song, co-founder and General Manager of Chengdu-based WestGene Biopharma.
Dr. Song was invited to share insights into WestGene's pioneering work in mRNA therapeutics at the Summit, with a particular focus on their leading EBV-related cancer mRNA therapeutic vaccine, WGc-043. In her keynote presentation, Dr. Song presented the latest research data and technological advancements of WGc-043, which has achieved IND milestones in both China and the US as the first mRNA therapeutic vaccine targeting EBV-related tumors.
During her presentation, Dr. Song highlighted the safety and efficacy of WGc-043 in treating NKT cell lymphoma (NKTCL) and nasopharyngeal carcinoma (NPC). She also discussed WestGene's breakthrough technologies in mRNA sequence design, novel delivery vectors, and scalable manufacturing that ensure high standards of safety and efficacy for their vaccine.
More on eTravel Wire
In addition to discussing their specific developments in mRNA therapeutics, Dr. Song also addressed broader challenges and opportunities within the industry. She emphasized the need to improve protein expression and delivery system efficiency while reducing production costs. Dr. Song also stressed the importance of balancing efficacy and safety, a principle that has guided WestGene's R&D efforts from the beginning.
Dr. Song also highlighted WestGene's collaborative approach to advancing mRNA therapeutics. This includes pipeline licensing for access to validated candidates, co-development projects that leverage combined expertise, and technology licensing for partners to use WestGene's cutting-edge solutions in their own developments.
The Summit featured extensive discussions on various indications for mRNA therapeutics including oncological, rare, and infectious diseases. Dr. Song concluded, "Presenting our research at such a platform is very meaningful. mRNA technology offers new hope and options for the treatment of malignancies, and our studies underscore the immense potential of this therapy in terms of safety and efficacy."
WestGene Biopharma remains committed to pushing the boundaries of mRNA therapeutics, leveraging its proprietary technologies and collaborative framework to bring transformative therapies to patients worldwide. With their groundbreaking work in mRNA therapeutics, WestGene Biopharma continues to be a leader in the global industry.
Dr. Song was invited to share insights into WestGene's pioneering work in mRNA therapeutics at the Summit, with a particular focus on their leading EBV-related cancer mRNA therapeutic vaccine, WGc-043. In her keynote presentation, Dr. Song presented the latest research data and technological advancements of WGc-043, which has achieved IND milestones in both China and the US as the first mRNA therapeutic vaccine targeting EBV-related tumors.
During her presentation, Dr. Song highlighted the safety and efficacy of WGc-043 in treating NKT cell lymphoma (NKTCL) and nasopharyngeal carcinoma (NPC). She also discussed WestGene's breakthrough technologies in mRNA sequence design, novel delivery vectors, and scalable manufacturing that ensure high standards of safety and efficacy for their vaccine.
More on eTravel Wire
- $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
- LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
- Marc Soucy's Newest Music Series Approaches Its One Year Mark
- Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities
- Award-winning NJ Author Celebrates New Release and Multi-Author Collaboration
In addition to discussing their specific developments in mRNA therapeutics, Dr. Song also addressed broader challenges and opportunities within the industry. She emphasized the need to improve protein expression and delivery system efficiency while reducing production costs. Dr. Song also stressed the importance of balancing efficacy and safety, a principle that has guided WestGene's R&D efforts from the beginning.
Dr. Song also highlighted WestGene's collaborative approach to advancing mRNA therapeutics. This includes pipeline licensing for access to validated candidates, co-development projects that leverage combined expertise, and technology licensing for partners to use WestGene's cutting-edge solutions in their own developments.
The Summit featured extensive discussions on various indications for mRNA therapeutics including oncological, rare, and infectious diseases. Dr. Song concluded, "Presenting our research at such a platform is very meaningful. mRNA technology offers new hope and options for the treatment of malignancies, and our studies underscore the immense potential of this therapy in terms of safety and efficacy."
WestGene Biopharma remains committed to pushing the boundaries of mRNA therapeutics, leveraging its proprietary technologies and collaborative framework to bring transformative therapies to patients worldwide. With their groundbreaking work in mRNA therapeutics, WestGene Biopharma continues to be a leader in the global industry.
0 Comments
Latest on eTravel Wire
- Cycurion Wins $33M Cybersecurity Contract for State Colleges, Also $6M from Transportation Agency: Cycurion, Inc. (Stock Symbol: CYCU) is Undervalued
- Novel 'We Won't Go Back' Published; Addresses Women's Issues
- Call for Papers Deadline Approaching – Don't Miss Your Shot to Speak at the OpenSSL Conference 2025!
- Century Cruises Opens New Office in South Florida
- The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
- AUACOM Signs a Statement of Shared Interest with BMCC
- Hypercard Announces Partnership with Priority Pass to Enhance Corporate Travel Experience
- WWSG Announces Exclusive Speaking Partnership with Patrick McGee, Author of 'Apple in China'
- Multi-Billion Dollar Drone Cleaning Market Addressed via New UAE Office, AI Drone and Quantum Computing Solutions in Varied Industries ZenaTech, Inc
- Spac Recovery Co. Files $590 Million Lawsuit Against Blackstone Products, Nomura , Franklin Square, Oaktree et al
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Sparking Disruptive Innovation in Web3
- The Cookout At The Vineyard In Napa Valley!
- Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression
- Tribeca Film Festival Official Podcast Selection Lead Features Hollywood Stars, Focuses On Ending Childhood Lead Poisoning In New York!
- Industrial Parts Fittings Champions the Revival of American Manufacturing
- $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD
- Pikmykid Launches $100,000 School Safety Grant Giveaway to Support K–12 Schools Across the U.S
- Bavarian Inn Lodge Recognized in 2025 TripAdvisor Travelers' Choice Awards
- Slotozilla Data Report: Unveiling 2024's Gaming Statistics
- BK Flooring Releases Their Top Reasons to Upgrade Kitchen Tile Flooring in 2025